2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid

Its key physicochemical properties include a melting point of 105.5-107°C, a predicted density of 1.378±0.06 g/cm³, a predicted pKa of 4.06±0.14, and a LogP value of 4.08640. It is soluble in organic solvents such as ethyl acetate and slightly soluble in water, providing a fundamental basis for its separation, purification, and reaction process design in pharmaceutical synthesis.

As a core pharmaceutical intermediate, it is mainly applied in the synthesis of two key drugs. It serves as an important intermediate for Netupitant, a potent NK1 receptor antagonist widely used in the treatment of chemotherapy-induced nausea and vomiting (CINV), which is usually combined with Palonosetron to enhance antiemetic efficacy. It is also a critical intermediate for Elinzanetant, a dual NK1/NK3 receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Additionally, it acts as a key structural building block to support the R&D of other NK1/NK3 receptor antagonists, laying a foundation for the development of new drugs for psychiatric disorders such as depression.